Jonathan Alspaugh, Chief Financial Officer at Aeglea BioTherapeutics, Inc. (AGLE), bought 75,000 shares at $2.08 ($156K) on 2022-03-11, disclosed to the SEC on 2022-03-15.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |